Frankfurt
17.03.25 | 08:52
3,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | OPTHEA LIMITED: Voluntary delisting from Nasdaq takes effect | 1 | ASX | ||
| Do | Opthea Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.11. | Opthea Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.11. | OPTHEA LIMITED: Results of AGM | 1 | ASX | ||
| OPTHEA LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 10.11. | Opthea Ltd - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
| 30.10. | OPTHEA LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 30.10. | Opthea Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.10. | OPTHEA LIMITED: Opthea announces intention to delist from Nasdaq | - | ASX | ||
| 27.10. | Opthea Appoints Hamish George As CFO | - | RTTNews | ||
| 26.10. | OPTHEA LIMITED: Appointment of Company Secretary and CFO | 1 | ASX | ||
| 15.10. | OPTHEA LIMITED: Long Term Suspended Entities | 1 | ASX | ||
| 09.10. | OPTHEA LIMITED: Notice of Annual General Meeting/Proxy Form | - | ASX | ||
| 06.10. | Opthea Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.10. | OPTHEA LIMITED: Opthea Receives A$10.8 million R&D Tax Incentive | 2 | ASX | ||
| 16.09. | OPTHEA LIMITED: Opthea - Annual General Meeting Date | 2 | ASX | ||
| 15.09. | Opthea Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 15.09. | Opthea Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 15.09. | OPTHEA LIMITED: 2025 Corporate Governance Statement | - | ASX | ||
| 15.09. | OPTHEA LIMITED: Annual Report to shareholders | - | ASX | ||
| 05.09. | OPTHEA LIMITED: S&P DJI Announces September 2025 Quarterly Rebalance | 2 | ASX |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 20,620 | +43,29 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,790 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 60,90 | -0,29 % | Halozyme Therapeutics, Inc.: Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery | Royalty revenue contribution expected to begin as early as 2030
Initial partner targets include derisked MoAs that are approved blockbusters today
Highly scalable... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| ABCELLERA BIOLOGICS | 3,047 | +0,46 % | Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? | ||
| GLOW LIFETECH | 0,026 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Achieves Debt-Free Status, Strengthening Balance Sheet and Enhancing Financial Flexibility for Growth | Toronto, Ontario--(Newsfile Corp. - November 19, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it has achieved debt-free status... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 276,50 | +0,55 % | Biodesix, Inc.: Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays | LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer | The newly created role marks a major step in CEO Kenneth Bilenberg's vision to scale Avid for its next chapter of growth.
TUSTIN, Calif., Nov. 10, 2025 /PRNewswire/... ► Artikel lesen | |
| BIOLINERX | 3,000 | -0,50 % | BioLine Rx's Earnings: A Preview | ||
| WHITEHAWK THERAPEUTICS | 1,730 | -4,95 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,660 | 0,00 % | Minerva Neurosciences, Inc: Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors | BURLINGTON, Mass., Nov. 19, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,230 | +2,18 % | Applied Therapeutics prüft strategische Optionen und kündigt Stellenabbau an | ||
| OVID THERAPEUTICS | 1,020 | -5,56 % | Ovid Therapeutics Inc.: Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results | Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT)... ► Artikel lesen | |
| GEOVAX LABS | 0,393 | -1,97 % | GeoVax GAAP EPS of -$0.31 misses by $0.04 |
Das Unternehmen OPTHEA LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OPTHEA LIMITED ADR finden Sie auf Wallstreet Online.